Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S34, 2019. DOI: 10.25251/skin.3.supp.34. Disponível em: https://skin.dermsquared.com/skin/article/view/761. Acesso em: 7 apr. 2025.